{"entity":{"id":"nct05263960","kind":"trial","name":"A Study of CM350 in Patients With Advanced Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of CM350 group1 in advanced solid tumours, run by Keymed Biosciences Co.Ltd, now recruiting.","summary":"A Study of CM350 in Patients With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT05263960 by Keymed Biosciences Co.Ltd, with 248 participants planned, started 2022-04-21 and due to reach its primary completion in 2027-04. Interventions recorded: CM350 group1, CM350 group2 and CM350 group3.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05263960","url":"https://clinicaltrials.gov/study/NCT05263960"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["keymed"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05263960","phase":"1/2","setting":"A Multicenter, Open Label, Phase I/II Clinical Study of CM350 in Patients With Advanced Solid Tumors","sponsor":"Keymed Biosciences Co.Ltd","enrolled":248,"outcomes":[]},"route":"/trials/nct05263960/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"company":[{"id":"keymed","kind":"company","name":"Keymed Biosciences (KYM Biosciences)","route":"/companies/keymed/"}]}}